Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06312774

Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia

Feasibility Study for Comparative Analysis of Proteome and Single-cell RNA Sequencing in Chronic Lung Disease Patients With and Without Sarcopenia

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
49 (estimated)
Sponsor
University College, London · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Sarcopenia, the loss of muscle mass and strength with ageing, is a prevalent condition in older adults, particularly those with chronic lung diseases like COPD and interstitial lung disease. The condition exacerbates the decline in physical ability, leading to decreased mobility, impaired quality of life, and increased disability. Sarcopenia's prevalence varies across populations, estimated to affect up to 10% of adults over 60 worldwide, with higher rates reported in studies employing consensus definitions of sarcopenia. The prevalence is even higher in patients with chronic lung diseases, reaching up to 26.6%. Sarcopenia's impact on health-related quality of life has been widely investigated. The condition is associated with various comorbidities, including chronic heart failure, obesity, diabetes, and chronic kidney disease, all negatively impacting the quality of life. The proposed study's primary aim is to assess the feasibility of the FACS (finding, assessing, confirming, severity) approach in determining sarcopenia's prevalence in the chronic lung disease population. FACS includes screening, strength measurements, and bioelectrical impedance analysis (BIA) to confirm sarcopenia. The study will also explore potential mechanisms associated with sarcopenia in this population, using proteome and single-cell transcriptome profiles. These multi-omics approaches provide a comprehensive view of the cellular and molecular changes underlying sarcopenia.In particular, the study will evaluate patient acceptance, time efficiency of each test, and recruitment effectiveness. The outcomes will guide the design and execution of subsequent, larger studies and provide preliminary data for power calculation for the full-scale study.

Conditions

Interventions

TypeNameDescription
OTHERThis is observational studyThis is observational study

Timeline

Start date
2024-04-18
Primary completion
2025-11-07
Completion
2027-01-04
First posted
2024-03-15
Last updated
2024-03-15

Source: ClinicalTrials.gov record NCT06312774. Inclusion in this directory is not an endorsement.